DUBLIN–(BUSINESS WIRE)–The “Peanut Allergy: Outlook on Global Disease Burden and Therapies (Palforzia)” report has been added to ResearchAndMarkets.com’s offering.
The scope of this report includes an overview of peanut allergy management in comparison with Palforzia.
The report discusses technological, regulatory, and economic trends that are affecting the market. It also explains the major drivers of Palforzia immunotherapy.
This report provides a brief explanation of peanut allergy disorder with regional prevalence rates; discusses the different types of diagnostic tests and their applicability in diagnosing various allergens; and provides an overview of the growing immunotherapy market.
This report organizes information from diverse sources into a cohesive package that includes:
- A section on diagnostic products such as skin prick tests, specific IgE tests, and oral food challenge tests.
- An overview section on guidelines for the prevention of peanut allergy.
- Specific chapters focus on unmet needs, economic burden, emerging therapies, and regulatory structure.
- A company profile section that provides background information on companies active in the diagnostic and treatment arenas is also included.
The Report Includes:
- An overview of the global market for peanut allergy
- Analysis of current and future market dynamics of peanut allergy market and identification of key drivers, restraints and opportunities
- Coverage of disease background and epidemiology and discussion on disease burden of peanut allergy
- Discussion on technological, regulatory and competitive elements as well as economic trends affecting the future marketplace and pipeline analysis of new products
- Evaluation of current market trends, market size, market forecast and market share analysis of the key companies of the industry and their key market strategies
-
Profiles of major players of the industry, including Beckman Coulter Inc., GlaxoSmithKline and Hitachi Chemical Diagnostics Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary
Chapter 3 Overview
- Introduction to Peanut Allergy
- Etiology and Pathophysiology
- Etiology
- Pathophysiology
- Diagnosis of Peanut Allergy
- History
- Skin Prick Test (SPT)
- Specific IgE (sIgE)
- Component-Resolved Diagnosis (CRD)
- Oral Food Challenge
- The Basophil Activation Test
- Epidemiology
Chapter 4 Unmet Needs
- Current Unmet Needs in Managing Peanut Allergies
- What We Know
- Unmet Needs
- Emerging Treatments: Immunotherapies
- What We Know
- Unmet Needs
- Unintentional and Casual Exposures
- What We Know
- Unmet Needs
Chapter 5 The Economic Impact of Peanut Allergies
- Burden of Peanut Allergies
- Direct Medical and Indirect Costs
- Quality of Life
- Current and Future Management of Peanut Allergies: Implications for Managed Care
- Economic Analysis of Oral Immunotherapy
- Barriers to OIT
Chapter 6 Palforzia: Overview and Market Outlook
- Drug Overview
- Scientific Summary
- Mechanism of Action
- Therapeutic Trials on Safety and Efficacy
- Adverse Effects
- Dosage, Administration, and Cost
- Risk Evaluation and Mitigation Strategy
- Current Status of Palforzia
- Regulatory
- Commercialization
- Market Analysis
- Incidence of Peanut Allergy
- The Role of Parents
- The Role of Allergists
- The Role of Payers
- Large Addressable Market
- Sales Launch Curve
Chapter 7 Peanut Allergy Prevention Guidelines
- Australia
- U.S. and Canada
- Addendum Guideline 1
- Addendum Guideline 2
- Addendum Guideline 3
Chapter 8 Emerging Therapies
- Viaskin Peanut: DBV Technologies
- Product Description
- Clinical and Regulatory Activities
- CA002: Camallergy
- Product Description
- Clinical and Regulatory Activities
- PRT100: ProTA Therapeutics
- Product Description
- Clinical and Regulatory Activities
- Dupixent (Dupilumab): Regeneron
- Product Description
- Clinical and Regulatory Activities
Chapter 9 Regulatory Structure
- Regulations in U.S.
- New Drug Approval
- The FDA Modernization Act of 1997
- Fast Track Status
- Special Protocol Assessments
- New Surveillance and Safety Requirements
- Medicare
- Regulations in Europe
- Pricing and Reimbursement
- Regulations in Japan
Chapter 10 Company Profiles
- Aimmune Therapeutics Inc.
- Alere Inc.
- Allergan Pharmaceuticals
- Alk-Abello A/S
- Allergopharma
- Ani Biotech Oy
- Beckman Coulter/Danaher
- Diagnostic Automation/Cortez Diagnostics Inc.
- Glaxosmithkline
- Hitachi Chemical Diagnostics Inc.
- Jubilant Hollisterstier
- Laboratory Corp. Of America Holdings
- Lincoln Diagnostics Inc.
- Quest Diagnostics
- Siemens Healthcare
- Smartpractice Denmark
- Taro Pharmaceutical Industries
- Terumo Medical Corp.
For more information about this report visit https://www.researchandmarkets.com/r/qnfim6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900